阿德福韦治疗拉米夫定耐药慢性乙型肝炎的研究  

Study of Adefovir on chronic type B hepatitis with Lamivudine resistance

作　　者：张伟红[1] 赵年丰[2] 王凯 

机构地区：[1]浙江省松阳县人民医院,浙江松阳323400 [2]浙江大学医学院附属第一医院,浙江杭州310003 [3]杭州博康生物科技有限公司,浙江杭州310006

出　　处：《现代中西医结合杂志》2006年第22期3032-3033,3038,共3页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的观察阿德福韦治疗拉米夫定耐药(LAM-R)慢性乙型肝炎(慢乙肝)的疗效。方法以ADV与LAM联合与单独用药治疗LAM-R慢乙肝250例,以治疗中的维持联合应答(HBV-DNA阴转率与ALT复常率)同步作完成治疗分析(ITT)与意向治疗分析(PP)。结果ADV对LAM-R慢乙肝的维持联合应答率48周达55%,96周达75%,96周未发现ADV-R基因耐药。结论ADV是目前治疗LAM-R慢乙肝的有效药物。Objective It is to observe the curative effect of Adefovir （ADV） on chronic type B hepatitis with Lamivudine resistance （LAM R）. Methods 250 patients with chronic type B hepatitis complicating with LAM- R were treated with ADV or LAM alone or with both the drugs. Per protocol analysis and intended to treat were performed on synchronicly according to maintaining combined response during treatment （negative rate of HBV DNA and recovery rate of ALT）. Results The maintaining combined response rate of ADV to LAM - R chronic type B hepatitis was 55 % in 48 weeks and 75 % in 96 weeks. No ADV R was found at the end of 96 weeks. Conclusion ADV is an effective drug for LAM R chronic type B hepatitis at present.

关 键 词：阿德福韦 拉米夫定 慢性乙型肝炎 耐药 

分 类 号：R512.62[医药卫生—内科学]